Calton & Associates’s Biogen BIIB Stock Holding History

Calton & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-132	Closed	-$45K	–	437
2017 Q4	$45K	Buy	+132	New	+$42.3K	0.01%	708

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Calton & Associates's BIIB Position: Q1 2018 in Review

Calton & Associates sold out of Biogen (BIIB) in Q1 2018, closing a stake of 132 shares — an estimated $45K sold.

Calton & Associates first reported a position in BIIB in Q4 2017 and held it in 1 quarter. The position peaked at $45K in Q4 2017. 1,103 funds tracked by Wall St. Rank hold BIIB as of Q1 2018.

Calton & Associates reported no remaining Biogen position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 132 Biogen shares in Q1 2018, an estimated $45K.
Calton & Associates first reported a position in Biogen in Q4 2017 and held it in 1 quarter.
Calton & Associates's Biogen position peaked at $45K in Q4 2017.
1,103 funds tracked by Wall St. Rank held Biogen as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.